Skip to main content
. 2021 Feb 15;18(1):105–119. doi: 10.20892/j.issn.2095-3941.2020.0098

Figure 1.

Figure 1

HBXIP is upregulated in non-small cell lung cancer (NSCLC) specimens and correlates with cancer progression. (A) Immunohistochemical staining of HBXIP in NSCLC samples, adjacent samples, and inflammatory pseudotumor samples. Representative images with different HBXIP staining intensities are shown. (B) Overall survival and disease-free survival were analyzed for NSCLC patients with different HBXIP expression levels. HBXIP level was scored as two grades [low (a final score < 3) and high (a final score of 4–12)] by multiplying the percentage of positive cells and the immunostaining intensity value.